Cardamonin inhibits angiotensin II-induced vascular smooth muscle cell proliferation and migration by downregulating p38 MAPK, Akt, and ERK phosphorylation. 2014

Yan-Jing Shen, and Xue-Xin Zhu, and Xian Yang, and Bo Jin, and Jin-Jian Lu, and Bin Ding, and Zhi-Shan Ding, and Su-Hong Chen
College of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, China.

Cardamonin is a chalconoid isolated from various herbs, such as Alpinia katsumadai and Carya cathayensis Sarg. This study examined the effect of cardamonin on angiotensin II (Ang II)-induced proliferation and migration in rat vascular smooth muscle cells (VSMCs) as well as its underlying mechanisms. The results showed that cardamonin significantly inhibited Ang II-induced proliferation and migration in rat VSMCs in a concentration-dependent manner. Moreover, cardamonin suppressed Ang II-induced phosphorylation of p38 MAPK, Akt, and extracellular regulated protein kinase (ERK). These findings indicate that the downregulation of p38 MAPK, Akt, and ERK phosphorylation might be, at least in part, involved in cardamonin-suppressed proliferation and migration induced by Ang II in rat VSMCs. As proliferation and migration of VSMCs play critical roles in the pathogenesis of atherosclerosis, cardamonin might be a potential candidate for atherosclerosis treatment.

UI MeSH Term Description Entries
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D047188 Chalcones Derivatives of CHALCONE that are important intermediates in the formation of FLAVONOIDS with anti-fungal, anti-bacterial, anti-inflammatory, and anti-tumor properties. 1,3-Diphenyl-propanediones,1,3-Diphenyl-propenones,1,3-Diphenylpropanediones,1,3-Diphenylpropenones,Chalconoids,1,3 Diphenyl propanediones,1,3 Diphenyl propenones,1,3 Diphenylpropanediones,1,3 Diphenylpropenones

Related Publications

Yan-Jing Shen, and Xue-Xin Zhu, and Xian Yang, and Bo Jin, and Jin-Jian Lu, and Bin Ding, and Zhi-Shan Ding, and Su-Hong Chen
January 2011, Evidence-based complementary and alternative medicine : eCAM,
Yan-Jing Shen, and Xue-Xin Zhu, and Xian Yang, and Bo Jin, and Jin-Jian Lu, and Bin Ding, and Zhi-Shan Ding, and Su-Hong Chen
September 2004, European journal of pharmacology,
Yan-Jing Shen, and Xue-Xin Zhu, and Xian Yang, and Bo Jin, and Jin-Jian Lu, and Bin Ding, and Zhi-Shan Ding, and Su-Hong Chen
February 2020, Clinical and experimental pharmacology & physiology,
Yan-Jing Shen, and Xue-Xin Zhu, and Xian Yang, and Bo Jin, and Jin-Jian Lu, and Bin Ding, and Zhi-Shan Ding, and Su-Hong Chen
June 2014, Journal of the renin-angiotensin-aldosterone system : JRAAS,
Yan-Jing Shen, and Xue-Xin Zhu, and Xian Yang, and Bo Jin, and Jin-Jian Lu, and Bin Ding, and Zhi-Shan Ding, and Su-Hong Chen
December 2019, Journal of cellular physiology,
Yan-Jing Shen, and Xue-Xin Zhu, and Xian Yang, and Bo Jin, and Jin-Jian Lu, and Bin Ding, and Zhi-Shan Ding, and Su-Hong Chen
August 2004, American journal of physiology. Cell physiology,
Yan-Jing Shen, and Xue-Xin Zhu, and Xian Yang, and Bo Jin, and Jin-Jian Lu, and Bin Ding, and Zhi-Shan Ding, and Su-Hong Chen
September 2015, Clinical hemorheology and microcirculation,
Yan-Jing Shen, and Xue-Xin Zhu, and Xian Yang, and Bo Jin, and Jin-Jian Lu, and Bin Ding, and Zhi-Shan Ding, and Su-Hong Chen
March 2016, Journal of cardiovascular pharmacology and therapeutics,
Yan-Jing Shen, and Xue-Xin Zhu, and Xian Yang, and Bo Jin, and Jin-Jian Lu, and Bin Ding, and Zhi-Shan Ding, and Su-Hong Chen
November 2014, Experimental and therapeutic medicine,
Yan-Jing Shen, and Xue-Xin Zhu, and Xian Yang, and Bo Jin, and Jin-Jian Lu, and Bin Ding, and Zhi-Shan Ding, and Su-Hong Chen
July 2010, Molecular and cellular biochemistry,
Copied contents to your clipboard!